Laffer Tengler Investments’s Cardiff Oncology CRDF Stock Holding History

Laffer Tengler Investments’s Portfolio CRDF Stock Details CRDF Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-21	Closed	-$32	–	429
2022 Q3	$32	Hold	21	–	–	﹤0.01%	428
2022 Q2	$46	Hold	21	–	–	﹤0.01%	386
2022 Q1	$52	Hold	21	–	–	﹤0.01%	417
2021 Q4	$126	Hold	21	–	–	﹤0.01%	381
2021 Q3	$139	Buy	+21	New	+$132	﹤0.01%	481

Other funds holding CRDF

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

LCM

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Laffer Tengler Investments's CRDF Position: Q4 2022 in Review

Laffer Tengler Investments sold out of Cardiff Oncology (CRDF) in Q4 2022, closing a stake of 21 shares — an estimated $32 sold.

Laffer Tengler Investments first reported a position in CRDF in Q3 2021 and held it in 5 quarters. The position peaked at $139 in Q3 2021. 60 funds tracked by Wall St. Rank hold CRDF as of Q4 2022.

Laffer Tengler Investments reported no remaining Cardiff Oncology position as of Q4 2022 after selling out during the quarter.
Laffer Tengler Investments sold 21 Cardiff Oncology shares in Q4 2022, an estimated $32.
Laffer Tengler Investments first reported a position in Cardiff Oncology in Q3 2021 and held it in 5 quarters.
Laffer Tengler Investments's Cardiff Oncology position peaked at $139 in Q3 2021.
60 funds tracked by Wall St. Rank held Cardiff Oncology as of Q4 2022.

Based on Laffer Tengler Investments's 13F filing for Q4 2022, filed 10 Feb 2023.